Clinical Trial: A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC

U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07062328) titled 'A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC' on July 02.

Brief Summary: The study aims to evaluate the efficacy and safety of Recaticimab and Adebrelimab in Combination With chemotherapy in patients with metastatic biliary tract carcinoma (BTC).

Study Start Date: July 10

Study Type: INTERVENTIONAL

Condition: Biliary Tract Carcinoma

Intervention: DRUG: Recaticimab and Adebrelimab

Patients would receive Recaticimab (150 mg, sc., q4w) and Adebrelimab (1200 mg, iv., q3w) plus GP chemotherapy in 21day cycles.

Recaticimab and Adebrelimab would be maintained until the di...